Merck KGaA, Darmstadt, Germany: Multiple Sclerosis trials

The registry lists 96 Multiple Sclerosis studies with Merck KGaA, Darmstadt, Germany as lead sponsor. 0 are open to participants now and 56 have results posted.

Phase 1 2Phase 2 12Phase 3 19Phase 4 17No phase 46(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)CompletedNCT04997148Results posted
• Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)CompletedNCT04934800Results posted
• Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)CompletedNCT04783935Phase 4Results posted
• Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)CompletedNCT04776213Phase 4Results posted
• Study of Evobrutinib in Participants With RMS (evolutionRMS 2)TerminatedNCT04338061Phase 3Results posted
• Study of Evobrutinib in Participants With RMS (evolutionRMS 1)TerminatedNCT04338022Phase 3Results posted
• Study of Evobrutinib in Participants With RMSTerminatedNCT04032171Phase 3Results posted
• Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)TerminatedNCT04032158Phase 3Results posted
• Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)CompletedNCT03961204Phase 4Results posted
• A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)CompletedNCT03933215Results posted
• A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)CompletedNCT03933202Results posted
• Effects of Cladribine Tablets on the PK of Microgynon®CompletedNCT03745144Phase 1Results posted
• A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)TerminatedNCT03387046Phase 2Results posted
• Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)CompletedNCT03369665Phase 4Results posted
• Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)CompletedNCT03364036Phase 4Results posted
• A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple SclerosisTerminatedNCT02975349Phase 2Results posted
• MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)TerminatedNCT02949908Results posted
• Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™CompletedNCT02254304Phase 4Results posted
• RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl FumarateTerminatedNCT02117050Phase 4Results posted
• A Study of Rebif® in Subjects With Relapsing Multiple SclerosisCompletedNCT02064816Phase 4Results posted
• Rebif® Rebidose® Versus Rebiject II® Ease-of-UseCompletedNCT02019550Phase 4Results posted
• ATX-MS-1467 in Multiple SclerosisCompletedNCT01973491Phase 2Results posted
• Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)TerminatedNCT01963611Phase 2Results posted
• A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ DeviceCompletedNCT01791244Phase 4Results posted
• Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1aCompletedNCT01514370Phase 2Results posted
• Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® TreatmentCompletedNCT01285401Phase 2Results posted
• Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedNCT01226745Phase 2Results posted
• Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)CompletedNCT01207648Results posted
• Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis PatientsCompletedNCT01201343Phase 4Results posted
• A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times WeeklyCompletedNCT01198132Phase 2Results posted
• A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After MitoxantroneCompletedNCT01142466Phase 4Results posted
• Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]TerminatedNCT01134627Phase 2Results posted
• Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot TrialCompletedNCT01085318Phase 4Results posted
• A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use StudyCompletedNCT01036165Phase 3Results posted
• The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics TrialCompletedNCT01034579Phase 4Results posted
• Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical TrialsCompletedNCT01013350Results posted
• The Multicenter, Open-label, Single-use Autoinjector Convenience StudyCompletedNCT00958009Phase 3Results posted
• Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis SubjectsCompletedNCT00938366Phase 1Results posted
• Atacicept in Multiple Sclerosis Extension Study, Phase IITerminatedNCT00853762Phase 2Results posted
• Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)CompletedNCT00813709Phase 3Results posted
• 12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.CompletedNCT00735007Phase 3Results posted
• Oral Cladribine in Early Multiple Sclerosis (MS)CompletedNCT00725985Phase 3Results posted
• A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)TerminatedNCT00642902Phase 2Results posted
• CLARITY Extension StudyCompletedNCT00641537Phase 3Results posted
• Transition to Rebif New FormulationCompletedNCT00619307Phase 3Results posted
• Rebif New Formulation (RNF) Quality of Life (QOL) StudyCompletedNCT00472797Phase 3Results posted
• A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple SclerosisCompletedNCT00441103Phase 3Results posted
• A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)CompletedNCT00436826Phase 2Results posted
• RNF and Betaseron® Tolerability StudyCompletedNCT00428584Phase 3Results posted
• REbif FLEXible Dosing in Early Multiple Sclerosis (MS)CompletedNCT00404352Phase 3Results posted
• Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple SclerosisCompletedNCT00367484Phase 4Results posted
• Rebif® Pregnancy RegistryCompletedNCT00338741Results posted
• Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis PatientsCompletedNCT00262314Results posted
• A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)CompletedNCT00213135Phase 3Results posted
• Rebif New Formulation (RNF) in Relapsing Forms of Multiple SclerosisCompletedNCT00110396Phase 3Results posted
• Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple SclerosisCompletedNCT00078338Phase 4Results posted
• Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)Active, not recruitingNCT05797740
• Next-Gen MS: Feed-forward PRO Data for MS ResearchTerminatedNCT04907305
• The MS-LINK™ Outcomes StudyCompletedNCT04735406
• Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and LymphocytesCompletedNCT03284970
• Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)CompletedNCT02921035
• Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)TerminatedNCT02394782
• Adherence Trial With MS LifeLines ® ServicesTerminatedNCT01905527
• Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) PatientsCompletedNCT01601119
• An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection DeviceCompletedNCT01601080
• Assessment of Patient Use of a New Device: RebiSmartCompletedNCT01195870
• Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy DemonstrationCompletedNCT01195857
• A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple SclerosisCompletedNCT01142583
• An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple SclerosisCompletedNCT01142557
• An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With MitoxantroneCompletedNCT01142518
• A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)CompletedNCT01142492
• An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) PatientsCompletedNCT01142453
• An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® TherapyCompletedNCT01141751
• Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis SubjectsCompletedNCT01128075
• A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) SubjectsCompletedNCT01125475
• An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year PeriodCompletedNCT01112657
• An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These ParametersCompletedNCT01112345
• An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)CompletedNCT01110993
• An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.CompletedNCT01108887
• Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.CompletedNCT01101776
• A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 YearsCompletedNCT01084798
• Rebif Compliance Support Program - Assessing Needs in Multiple SclerosisCompletedNCT01080573
• Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)CompletedNCT01080053
• To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis PatientsCompletedNCT01080040
• Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)CompletedNCT01080027
• Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in ArgentinaCompletedNCT01080014
• A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in ArgentinaCompletedNCT01080001
• To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple SclerosisCompletedNCT01079975
• Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®CompletedNCT01075880
• An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their CaregiversCompletedNCT01075737
• Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple SclerosisCompletedNCT01074346
• Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial (PRISMS-15)CompletedNCT01034644
• A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without TreatmentCompletedNCT00702065
• A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)CompletedNCT00292266Phase 3
• Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis SubjectsCompletedNCT00292253Phase 3
• Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) SubjectsWithdrawnNCT00101959Phase 4